Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.
Department of Medicine, University of Chicago, IL 60637.
W M
WM
Stadler
N J
NJ
Vogelzang
D000818:Animals; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic / Q000706:statistics & numerical data; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000276:immunology; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*
D016898:Interferon-alpha; D007376:Interleukin-2